`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`MYLAN INSTITUTIONAL LLC,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`______________
`
`Case IPR2020-00324
`Patent 8,114,833
`______________
`
`PATENT OWNER’S UPDATED MANDATORY NOTICE INFORMATION
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2020-00324
`Patent 8,114,833 B2
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), Patent Owner, Novo Nordisk A/S
`
`(“Novo Nordisk”), hereby files its first Updated Mandatory Notice:
`
`I.
`
`Related Matters (§ 42.8(b)(2))
`
`Patent Owner is aware of the following district court litigations involving U.S.
`
`Patent No. 8,114,833: Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan
`
`Institutional LLC, No. 19-cv-1551-CFC (D. Del.); Novo Nordisk Inc. and Novo
`
`Nordisk A/S v. Mylan Institutional LLC, No. 19-cv-164 (N.D. W. Va.); Novo Nordisk
`
`Inc. and Novo Nordisk A/S v. Sandoz Inc., No. 20-cv-747-CFC (D. Del.); Novo
`
`Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc., 20-cv-6842-RMB-AMD (D.N.J.).
`
`Case Nos. 19-cv-1551-CFC, 20-cv-747-CFC, and 20-cv-6842-RMB-AMD are
`
`currently pending. Case No. 19-cv-164 has been voluntarily dismissed.
`
`U.S. Patent Application No. 16/260,204, which is pending and was filed on
`
`January 29, 2019, and U.S. Patent Application No. 16/910,945, which is pending
`
`and was filed on June 24, 2020, both claim the benefit of U.S. Application No.
`
`11/435,977, which is the application that issued as U.S. Patent No. 8,114,833.
`
`II. Counsel and Service Information (§§ 42.8(b)(3) and (4))
`
`Patent Owner will maintain its lead and backup counsel as shown below:
`
`
`
`1
`
`
`
`
`
`IPR2020-00324
`Patent 8,114,833 B2
`
`Lead Counsel:
`Jeffrey J. Oelke, Reg. No. 37,409
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`Tel: (212) 430-2600
`Fax: (650) 938-5200
`joelke@fenwick.com
`
`Backup Counsel:
`Ryan P. Johnson
`Laura T. Moran
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`ryan.johnson@fenwick.com
`laura.moran@fenwick.com
`
`
`
`Please address all correspondence to the lead and backup counsel at the above
`
`addresses and to Novo833IPR@fenwick.com. Patent Owner consents to electronic
`
`service to the e-mail addresses above for lead and backup counsel and to
`
`Novo833IPR@fenwick.com.
`
`Dated: June 29, 2020
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`joelke@fenwick.com
`
`Counsel for Novo Nordisk A/S
`
`
`
`2
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s
`
`Updated Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on June
`
`29, 2020, by filing this document through the Patent Trial and Appeal Board End to
`
`End System, as well as delivering a copy via electronic mail upon the following
`
`attorneys of record for the Petitioner:
`
`Brandon M. White
`Lara Dueppen
`Perkins Coie LLP
`white-ptab@perkinscoie.com
`dueppen-ptab@perkinscoie.com
`liraglutide@perkinscoie.com
`
`
`Date: June 29, 2020
`
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`
`/ Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`
`Counsel for Novo Nordisk A/S
`
`
`
`
`
`